Introduction
Solid tumors require an adequate vascular supply to grow beyond a certain dimension (Folkman and Klagsburn, 1987; Folkman, 1990) . Formation of new blood vessels is mediated by soluble angiogenic factors released from tumor cells and/or from tumor-infiltrating in¯ammatory cells such as macrophages and mast cells (Folkman and Shing, 1992) . These factors stimulate the migration and the proliferation of endothelial cells by activating speci®c cell surface receptors (Risau, 1997) .
Vascular endothelial growth factor (VEGF) is a dimer of 35 ± 46 kDa composed of one pair of four possible monomers generated by a dierential splicing of a single primary transcript (Tisher et al., 1991) . VEGF stimulates proliferation of endothelial cells in vitro and promotes angiogenesis in vivo (Ferrara and Henzel, 1989; Gospodarowicz et al., 1989; Keck et al., 1989) . VEGF exerts its eects by interacting with two high anity tyrosine kinase receptors of Class III (Flt-1 and Flk-1/KDR) expressed preferentially in endothelial cells (Shibuya et al., 1990; De Vries et al., 1992) .
VEGF and its receptors play a pivotal role in tumor angiogenesis. VEGF is abundantly expressed by most human and experimental tumors (Plate et al., 1992; Berkman et al., 1993; Brown et al., 1993; Olson et al., 1994) ; the coordinated expression of VEGF protein(s) by tumor and stromal cells and of both VEGF receptors in tumor blood vessels suggests the existence of a paracrine stimulatory loop which supports the development of a tumor vascular bed; the neutralization of VEGF by dierent strategies markedly reduces the in vivo growth of tumor cells (Kim et al., 1993; Millauer et al., 1994) . These considerations suggest that interference with the paracrine circuit established by the VEGF/VEGF receptor system might provide an attractive experimental opportunity for therapeutic intervention in tumors that show little response to conventional therapies.
Thyroid carcinomas comprise a broad spectrum of tumors ranging from dierentiated papillary and follicular carcinomas, with a generally good clinical outcome, to fatal aggressive anaplastic carcinomas (Hedinger et al., 1988) . Anaplastic carcinomas are characterized by cellular proliferation, increased vascularization and focal necrosis. Current treatment of thyroid anaplastic carcinoma patients, such as surgery and chemiotherapy, only provide short-term management of the disease (De Vita et al., 1997) . Thus, the development of new adjuvant therapies may be crucial for the treatment of patients aected with anaplastic tumors of the thyroid gland.
We have previously reported that VEGF expression is upregulated in human goiters and in an animal model of thyroid goitrogenesis (Viglietto et al., 1997) , as well as in thyroid carcinomas (Viglietto et al., 1995) . In this study we have addressed the role of VEGF in the development of thyroid tumors by two complementary approaches. First, we studied the eects exerted by constitutive overexpression of VEGF into a cell line known to express low VEGF levels and to be weakly malignant (Viglietto et al., 1995) . Second, we determined the eects exerted by inhibiting VEGF expression with an antisense methodology on the tumorigenicity of the ARO cells (which produces highly vascularized tumors within a few days). The results reported here demonstrate the primary role exerted by VEGF in angiogenesis associated with the development of thyroid tumors and indicate the possibility that therapeutic intervention directed against VEGF may result in a severe reduction of the in vivo growth of anaplastic carcinomas of the thyroid gland. 
Results

Generation and characterization of modi®ed NPA cell lines
We have previously shown that in thyroid cancer and tumor-derived cell lines, VEGF expression is associated with high degree of malignancy, suggesting that progression of thyroid tumors is associated with VEGF overexpression (Viglietto et al., 1995) . To address more directly the role of VEGF expression in thyroid tumorigenesis, we followed two complementary approaches. First, we overexpressed VEGF in a cell line, NPA, shown to express low levels of VEGF mRNA (Viglietto et al., 1995) and to be poorly tumorigenic and investigated whether VEGF overexpressing NPA cells acquired a more malignant phenotype. To this aim, NPA cells were electroporated using a CMV-based vector encoding VEGF 121 cDNA in 5' ± 3' orientation (CMV VEGF S) and the transfected cells were selected with G418 ( Figure 1a ). Northern blot analysis revealed that, compared to untransfected NPA or NPA-CMV1 and CMV-2 clones transfected with the backbone vector, 9/10 analysed clones expressed a higher level of a transcript of about 1.3 kb encoding exogenous VEGF (data not shown). Furthermore, by RT ± PCR, using two primers designed on the vector DNA sequencē anking the polylinker site, we unambiguously demonstrated the expression of the transfected VEGF cDNA (Figure 1b) . Finally, to further characterize the VEGF expressing NPA clones, we analysed the conditioned medium of NPA, NPA-CMV1, NPA-S6 and NPA-S7 clones for the production of VEGF 121 by Western blot. Clones S6 and 7 showed increased production and secretion in the conditioned medium of the exogenous isoform VEGF 121 when compared to control cells (Figure 1c) .
We investigated whether the constitutive expression of VEGF into NPA cells conferred a growth advantage to NPA cells. To this aim, we determined the growth rate of NPA-CMV1, S6 and 7 clones compared to parental cells. Figure 1d shows the results from three dierent experiments performed in quadruplicate. Since no dierence was observed in the growth rate we concluded that overexpression of VEGF did not confer growth advantage to NPA cells.
Overexpression of VEGF in NPA cells enhances tumorigenicity by decreasing latency of tumor appearance and increasing tumor vascularization
The poorly malignant papillary carcinoma-derived cell line NPA produces tumors with long latency when injected in nude mice. We investigated whether the constitutive production of VEGF could render these cells fully tumorigenic by inoculating the parental untransfected NPA cells and their VEGF overexpressing derivatives S6 and 7 cells into nude mice and monitoring the appearance of tumors for several weeks.
Control cells (untransfected or transfected with the backbone vector) gave tumors with a latency of about 45 days (Table 1) in 3/5 and 3/6 mice, respectively. In contrast, when we inoculated S6 and 7 cells into nude mice, we obtained visible tumors in about 25 days; some mice had developed the tumors as early as 19 days in the case of S6 or 17 days in the case of S7 cells (Table 1) . After 3 months mice were sacri®ced and both the size and histology of tumors were analysed. The diameter of the tumors derived from VEGF-overexpressing cells was threefold larger than the diameter of tumors generated by control cells (Figure 2a ). The tumors generated by inoculation of control cells were in the range of 0.1 ± 0.3 g with a mean of 0.13+0.05 (for NPA cells) and of 0.16+0.11 (for NPA-CMV1 cells), whereas the VEGF-overexpressing cells gave tumors with an average size of 0.8 g ( Figure 2b and Table 1 ). Analysis by the Student t-test con®rmed the statistical signi®cance of the dierences shown by control or VEGF-overexpressing cells, both for latency of appearance of the tumors and for tumor mass (P50.001).
To exclude any other interference on the experimental model we performed a dose response curve by inoculating dierent numbers of VEGF-overproducing cells. S6 and 7 NPA cells were mixed at a ratio of 1 : 1 (0.5610 6 VEGF-overproducing cells) or 1 : 5 (0.2610 6 VEGF-overproducing cells) with untransfected NPA cells, respectively, inoculated into nude mice and tumor growth was monitored weekly. In all cases a total number of 1610 6 cells was inoculated. In the case of the 1 : 1 dilution tumors appeared with an intermediate latency (about 30 days) and their size was in an intermediate range, that is 0.1 ± 0.7 g (mean 0.47+0.26) in the case of S6 and 0.4 ± 0.9 g (mean 0.6+0.21) in the case of S7; conversely, in the case of 1 : 5 dilution the tumors appeared with a latency similar to that of CMV1-transfected NPA cells (about 40 days) and also their size was similar to those generated by parental NPA (0.12 ± 0.2 g) ( Figure 2b ). The statistical significance of the dierences shown by NPA tumors in this dose-response experiment was analysed using the Student t-test. A value of P50.001 was observed both for latency of appearance of the tumors and for tumor mass. Vascularization of tumors is expressed as the number of capillaries/®eld. The mean (+s.d.) is reported. For each tumor at least ten dierent ®elds were analysed for vessel number as described in Materials and methods. *Five mice were injected with NPA cells in two dierent experiments but only three tumors had grown. **Six mice were injected with NPA-CMV1 cells in two dierent experiments but only three tumors had grown. n.d. not done Subsequently, we analysed the vascularization of the tumors generated by the three types of cells, NPA, NPA-CMV1 and NPA-S6 and 7, respectively. To this aim tumor sections ( Figure 2c ) were stained with an antimouse PECAM monoclonal antibody which detects vascular endothelial cells in the tumor, as previously reported (Saleh et al., 1996) . The number of blood vessels was determined by counting the PECAM-stained vessels in ten dierent ®elds at 1006 magni®cation (0.2560.35 mm). As reported in Table 1 , tumors generated by NPA or NPA-CMV1 cells presented a signi®cantly lower number of blood vessels (P50.001) compared with VEGF overexpressing NPA cells. NPA cells showed an average number of seven blood vessels/®eld whereas VEGF overexpressing NPA cells showed an average of a threefold higher number of vessels/ ®eld (20.1+7.2 vessels for S6 cells, and 21.6+7.9 vessels for S7 cells, respectively). Finally, we measured the amount of necrosis present in each tumor section (Table 1) . In tumors derived from control cells we observed that approximately 40% of tumor tissue had undergone necrosis whereas in those derived from VEGF overexpressing cells, the necrotic fraction was signi®cantly lower (approximately 10%). 
Generation and characterization of modi®ed ARO cell lines
The second experimental approach to investigate the role of VEGF in thyroid carcinogenesis was to determine the eects of suppressing VEGF expression in cells with high levels of endogenous VEGF (Viglietto et al., 1995) . The thyroid carcinoma-derived cell line ARO is highly malignant and produces tumors with very short latency (Viglietto et al., 1995) . To suppress VEGF synthesis in ARO cells, we used the antisense methodology. ARO cells were stably transfected with a CMV-based vector which carried the VEGF cDNA in 3' ± 5' orientation ( Figure 3a) . After G418 selection, ten dierent clones were analysed by Northern blot and Western blot to determine VEGF expression (Figure 3b  and c) . As shown in Figure 3c , a strong reduction in the amount of VEGF protein in the conditioned medium of AS4 and AS6 ARO cells was observed compared to untransfected ARO cells, demonstrating that the antisense vector was indeed able to block the production of VEGF protein.
Finally, to investigate whether the down-regulation of VEGF expression was able to aect the growth potential of ARO cells, we measured the growth rate of untransfected parental ARO cells, and of the corresponding pCMV-transfected (ARO-CMV1) or pCMV VEGF AS-transfected cells (ARO AS4 and AS6 clones). As shown in Figure 3d , no modi®cation of the growth properties of the dierent types of ARO cells was observed.
Suppression of VEGF expression inhibits in vivo growth of ARO thyroid anaplastic cell lines
To test the eects exerted on the in vivo growth potential of ARO cells by the block of VEGF expression, we inoculated ARO cells or their transfected derivatives (CMV-transfected or VEGF antisense-transfected cells) into nude mice. The results are shown in Table 2 . Untransfected ARO cells injected in nude mice gave tumors after an average of 16.6 days (n=5). Similarly, ARO CMV1 cells gave tumors after 17.2 days (n=5). When ARO AS4 and AS6 cells were inoculated into nude mice, tumors grew with a longer latency. In fact, in the case of AS4, tumors appeared after an average of 33.5 days (n=8) and in the case of AS6, tumors appeared after 35.8 days (n=8). Strikingly, in the case of AS4, 2/8 injected mice did not give tumors at all. After 2 months, mice were sacri®ced, tumor size and vascularization degree and/or necrosis analysed. Tumors derived from ARO cells appeared to be fourfold larger than tumors derived from VEGF antisense-transfected cells, as shown in Figure 4a . These observations were con®rmed by the calculation of the size of the excised tumors expressed as g of tissue. The size of the tumors derived from ARO and ARO CMV1 cells was similar (average of 0.84 and 0.72 g respectively) and was approximately fourfold bigger than the size measured in tumors derived from AS4 and AS6 cell clones (0.2 and 0.25 g respectively) (Figure 4b) . A Student t-test analysis con®rmed the statistical signi®cance of the observed dierences, with P50.001.
Tumor sections were subsequently analysed for the extent of the associated vascularization by determining the number of blood vessels (Figure 4c ) using antimouse PECAM antibody to stain endothelial cells inside the tumors in ten dierent ®elds (0.2560.35 mm). We observed that in the tumors derived from AS4 and AS6 cells, there was a signi®cantly lower number of blood vessels compared with tumors derived from control cells (P50.001). In fact, in control cells the average of vessels/®eld was about 46 for ARO and 42 for CMV1 cells, respectively (Table 2) . Conversely, in VEGF antisense-derived tumors we found an average of 12 vessels/®eld in sections derived from AS4 and 15.5 from AS6 tumors. We also compared the amount of necrosis present in ARO and VEGF-antisense tumors. The area of necrosis of each tumor was measured by computer analysis on ®ve sections, and was expressed as a percentage of the section area. In ARO and ARO CMV1-derived tumors, we found an average necrosis of 10.5% and 15.8%, respectively. In contrast, tumors derived from VEGF-antisense cell lines were significantly more necrotic with an area ranging from 38+6.6 for AS6 and 45+9.6 for AS4.
Expression of VEGF receptors Flk-1/KDR and Flt-1 mRNAs in experimental thyroid tumors
So far, the results presented in this study suggest that the expression of VEGF represents a key event in an experimental model of thyroid tumorigenesis. To provide further evidence that neoangiogenesis induced in this experimental model was indeed dependent on VEGF expression, we investigated the presence of VEGF receptors Flt-1 and Flk-1/KDR in NPA-CMV1, NPA-S6 and S7 or ARO CMV1 and ARO AS4 and ARO AS6 cells. The expression of both receptors in NPA-or ARO-derived tumors was determined by semi-quantitative RT ± PCR analysis ( Figure 5 ). Tumors derived from NPA-CMV1 cells (which are poorly vascularized) express low levels of both VEGF receptors whereas tumors generated by VEGF overexpressing NPA cells S6 and S7 (which are highly vascularized) express increased levels of Flt-1 and Flk-1/KDR mRNAs (Figure 5a ). Conversely, inoculation of ARO cells into nude mice give rise to highly vascularized tumors. In this case, the expression of both VEGF receptors in ARO CMV1-derived tumors is high whereas it appears much reduced in the tumors derived from antisense ARO cells AS4 and AS6 (Figure 5b ). These results indicate that the expression of VEGF receptors Flk-1/KDR and Flt-1 is higher in vascularized tumors than in those poorly vascularized.
Discussion
The data presented here provide direct evidence that VEGF has an important role in facilitating the growth of thyroid tumors in vivo by stimulating tumor angiogenesis and that the neutralization of its expression by antisense methodology may represent a powerful mean to block the in vivo growth of thyroid anaplastic tumors.
The role of VEGF and its receptors (Flt-1 and Flk-1/ KDR) in the development of solid tumors is well Vascularization of tumors is expressed as the number of capillaries/®eld. The mean (+s.d.) is reported. For each tumor at least ten dierent ®elds were analysed for vessel number as described in Materials and methods. *Eight mice were injected with ARO AS4 cells in two dierent experiments but only six tumors had grown established. The currently accepted model proposes that tumor cells themselves and/or stromal cells secrete VEGF into interstitial¯uids. The secreted VEGF would bind to its receptors on the surface of host endothelial cells and stimulate the neoformation of blood vessels through a paracrine loop. Newly-formed capillaries supply growing tumor cells with nutrients and oxygen and collect waste materials, thus aecting their growth potential (Risau, 1997) .
The importance of the VEGF/VEGF receptors system is underscored by the observation that VEGF overexpression represents an almost universal event during tumor progression. Several studies have demonstrated that VEGF production occurs in almost all tumors and cell lines analysed including thyroid cancer (Plate et al., 1992; Brown et al., 1993; Olson et al., 1994; Viglietto et al., 1995) .
In the present study we investigated whether VEGF expression was sucient to enhance the tumorigenicity of a poorly tumorigenic cell line which expressed a low basal level of VEGF, the papillary NPA cell line. Therefore, we constitutively expressed VEGF into NPA cells and compared the tumorigenic potential of these cells with the corresponding parental cells. We observed that NPA VEGF S cells induced signi®cantly more angiogenesis than the parental NPA strain and, as a consequence, formed big, rapidly growing tumors when injected into immunode®cient mice. These results demonstrated that VEGF secreted by transfected NPA cells was not only eective in inducing angiogenesis but also sucient to enhance the tumorigenicity of the cells, thus providing experimental evidence that VEGF expression may represent a critical event in the development of thyroid tumors. In particular, overexpression of VEGF during tumor progression may lead to the acquisition of the so-called`angiogenic phenotype' which appears to be necessary for invasion and metastasis (Folkman and Shing, 1992) .
Since overexpression of VEGF occurs in most tumors and cell lines analysed, this endothelial growth factor appears to be a suitable molecular target for the development of anti-angiogenic therapeutic strategies. Indeed, the neutralization of VEGF activity either by the use of monoclonal anti-VEGF antibodies (Kim et al., 1993) , or the construction of a retrovirus carrying a dominant negative version of the¯k/KDR receptor (Millauer et al., 1994) , or antisense strategy (Saleh et al., 1996; Claey et al., 1996) has proven to be a powerful mean to block the in vivo growth of several cell lines with dierent histotypes.
Here, we report the results of experiments aimed at evaluating the feasibility of blocking the growth of thyroid neoplasms by interfering with tumor angiogenesis with antisense constructs which neutralize VEGF expression. VEGF could represent an ideal molecular target for the development of an anti-angiogenetic therapy of thyroid carcinomas since VEGF is increased in most thyroid tumors and cell lines and it seems sucient to enhance tumorigenicity of poorly tumorigenic cells.
The results reported in this study demonstrate that the neutralization of VEGF expression by antisense methodology was able to drastically aect the in vivo growth of a highly malignant cell line derived from an anaplastic thyroid carcinoma, the ARO cell line, which expresses high constitutive VEGF levels (Viglietto et al., 1995) . ARO cells grow rapidly when injected into nude mice and produce highly vascularized tumors with undierentiated histology. When VEGF expression was drastically reduced in ARO cells by antisense constructs, these cells lost most of their in vivo growth potential. In fact, tumors grew much slower and appeared after a longer latency. Furthermore, ARO AS tumors presented a strongly reduced vascularization compared to parental ARO cells. These ®ndings demonstrate that the reduction of VEGF secretion by antisense, induced less angiogenesis and the formation of small almost avascular tumors.
Furthermore, VEGF appears to be the principal mediator of tumor angiogenesis in thyroid tumors since the absence of VEGF cannot be adequately compensated for by other angiogenic growth factors (i.e. bFGF, PDGF or angiopoietin-1) (Davis et al., 1996) . Although angiopoietin-1 may cooperate with VEGF in inducing angiogenesis (Koblizek et al., 1998) , only recently has the role of the angiopoietin-1/Tie-2 system been investigated in tumor angiogenesis (Stratmann et al., 1998) and there are no data about angiopoietin-1 expression in thyroid tumors.
According to our data, it appears that the mechanism whereby VEGF enhances tumorigenicity in NPA cells is likely to be the result of the induction of tumor neoangiogenesis. In contrast to the report of Saleh et al. (1996) , VEGF was not able to confer growth advantage in vitro to thyroid tumor-derived cell lines, as if the eects exerted by the VEGF/VEGF receptors system were not directly exerted on the tumor cells themselves. It appears that VEGF expression modulates the process of tumor angiogenesis through the establishment of paracrine circuits involving VEGF secreting tumor cells and host endothelial cells which line tumor stromal blood vessels. On the basis of this model VEGF would be secreted by tumor cells and, interaction with its receptors on the surface of Figure 5 RT ± PCR analysis of Flt-1 and Flk-1/KDR gene expression in experimental thyroid tumors. Total RNA was retrotranscribed and subjected to 23 cycle PCR ampli®cation using Flt-1 (upper panel) or Flk-1/KDR-speci®c (middle panel) primer pairs in combination with aldolase-speci®c primers (lower panel). (a) Lane 1, control; lanes 2 and 3, RNA derived from two dierent tumors generated by NPA-CMV1 cells; lanes 4 and 5, RNA derived from two dierent tumors generated by NPA-S6 cells; lanes 6 and 7, RNA derived from two dierent tumors generated by NPA-S7 cells. (b) Lane 1, control; lanes 2 and 3, RNA derived from two dierent tumors generated by ARO CMV1 cells; lanes 4 and 5, RNA derived from two dierent tumors generated by ARO AS4 cells; lanes 6 and 7, RNA derived from two dierent tumors generated by ARO AS7 cells endothelial cells, would stimulate the neoformation of new blood vessels. Accordingly, high expression of the VEGF receptors was found in vascularized tumors such as those generated from NPA S and ARO CMV1 cells. Enhanced Flt-1 and Flk-1/KDR expression may either depend on the increased number of vessels present in highly vascularized tumors, or alternatively, may re¯ect a true overexpression of the Flt-1 and Flk-1/KDR receptors in tumor capillaries. In experimental models of rat glioma (Plate et al., 1993) and in liver metastasis of colon cancer (Warren et al., 1995) higher mRNA expression of Flt-1 and Flk-1/KDR has been detected in tumor vessels relative to the vessels in the adjacent unaected parenchyma. Thus, it is likely that the increased steady-state mRNA levels of Flt-1 and Flk-1/KDR receptors observed in these experimental thyroid tumors may be due to a true activation of Flt-1 and Flk-1/KDR genes.
In conclusion, our ®ndings demonstrate that VEGF expression is sucient and at the same time necessary for the growth of a thyroid tumor-derived cell line in vivo. Furthermore, since the inhibition of VEGF is sucient to control the growth of an anaplastic thyroid carcinoma cell line in vivo by the suppression of tumor associated vascularization, the VEGF antisense strategy oers feasible possibilities for gene therapy development as adjuvant treatment for malignant thyroid tumors.
Materials and methods
Cell lines and culture
The human thyroid carcinoma cell lines NPA and ARO (Pang et al., 1989) were grown in F12 medium supplemented with 5% fetal calf serum. Cell transfection was carried out by electroporation (300 mV and 975 mF for ARO and 250 mV and 975 mF for NPA). Stable transfectants were selected in 800 mg/ml of G418.
Construction of VEGF vectors
The human VEGF 121 cDNA was initially isolated from ARO cells by RT ± PCR. Ampli®ed DNA fragments were cloned into the pCRII vector and sequenced to verify the correct coding sequence. VEGF 121 cDNA was then cloned into the pcDNA-3 expression vector (Invitrogene Inc.) under the control of the CMV promoter in 5' ± 3' (sense vector) or 3' ± 5' (antisense vector) orientation.
RNA extraction, Northern blotting and hybridization
Total cellular RNA was isolated from cultured cell lines as previously described (Sambrook et al., 1989) . Northern blots were performed as described (Sambrook et al., 1989) . VEGF and GAPDH probes were radiolabeled with a random prime synthesis kit (Multi-Prime, Amersham Inc.). Hybridization reactions were performed as described (Viglietto et al., 1997) .
Western blot analysis
NPA and ARO cells were grown to semicon¯uence and conditioned media were obtained in serum-devoid medium and concentrated under vacuum. Eighty mg of proteins were electrophoresed by SDS ± PAGE and transferred to nitrocellulose membranes (Hybond-C, Amersham). Membranes were incubated with primary anti-VEGF polyclonal antibodies (Sigma Inc.) and developed with the enhanced chemioluminescence system (ECL, Amersham).
Tumor necrosis and vascularization analysis
Adult nude mice (nu/nu) of approximately 5 ± 8 weeks of age received s.c. injections of NPA or ARO cells or the corresponding transfected cells. Approximately 10 6 cells were injected s.c. into the¯anks of mice. Mice were monitored daily to determine tumor size. The percentage of necrosis present in each tumor was measured by computer analysis of each necrotic site and expressed as percentage of the area. The number of blood vessels/tumor section was calculated by counting the number of PECAM-positive vessels by light microscopy at a lower power (640). Calculations were performed on ten ®elds/section at a 1006 magni®cation (640 objective and 62.5 ocular, 0.2560.35 mm) and performed on two tumors per cell line in each independent experiment. A Student t-test was used to determine the statistical signi®cance of tumor growth rate and vascularization derived from parental and transfected cell lines.
Immunoperoxidase staining
Tumors were removed from mice and immediately frozen. Sections of 7 ± 10 mm were serially cut through the entire tumor and alternate sections were stained either with hematoxylin and eosin or by indirect immunoperoxidase, using the antimouse anti-PECAM antibody (Pharmingen, San Diego, CA, USA) which detects vascular endothelial cells in tumors. Immunohistochemistry was performed as previously reported (Saleh et al., 1996) .
